Live Breaking News & Updates on Clinica Sagrada Familia

Stay updated with breaking news from Clinica sagrada familia. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

First patient treated in CereVasc® clinical trial of eShunt® System for Normal Pressure Hydrocephalus

Press release content from PR Newswire. The AP news staff was not involved in its creation. ....

United States , Buenos Aires , Distrito Federal , Sagrada Familia , Tufts Medical Center , Dan Levangie , Clinica Sagrada Familia , Carl Heilman , Las Neurociencias , Pedro Lylyk , Adel Malek , Company Contact , University Of Buenos Aires , World Stroke Organization , Founder Of The Cerebrovascular Research , Hydrocephalus Association , Prnewswire Cerevasc Inc , Cerevasc Inc , Education Foundation , Foundation Fundaci , University Of Business , National Stroke Prevention Campaign , Argentine Stroke Association , Comprehension Stroke Center , Argentina National Administration Of Drugs , Shunt System ,

First patient treated in CereVasc® clinical trial of eShunt® System for Normal Pressure Hydrocephalus

Clinical trial underway in Argentina to study minimally invasive treatment for NPHBOSTON, April 25, 2022 /PRNewswire/ CereVasc, Inc., a private. ....

United States , Buenos Aires , Distrito Federal , Sagrada Familia , Tufts Medical Center , Dan Levangie , Clinica Sagrada Familia , Carl Heilman , Las Neurociencias , Pedro Lylyk , Adel Malek , National Stroke Prevention Campaign , Company Contact , Argentine Stroke Association , University Of Buenos Aires , World Stroke Organization , Comprehension Stroke Center , Founder Of The Cerebrovascular Research , Hydrocephalus Association , Cerevasc Inc , Education Foundation , Foundation Fundaci , Argentina National Administration Of Drugs , University Of Business , Normal Pressure Hydrocephalus , National Administration ,

First patient treated in CereVasc clinical trial of eShunt™ System for communicating hydrocephalus

First patient treated in CereVasc clinical trial of eShunt™ System for communicating hydrocephalus
Investigational device has the potential to transform a half-century-old standard of care
News provided by
Share this article
Share this article
BOSTON, Feb. 10, 2021 /PRNewswire/ CereVasc, Inc., a clinical-stage, medical device company developing novel, minimally invasive treatments for neurological diseases, has treated the first patient in a study of its eShunt System, an investigational device intended to treat communicating hydrocephalus (CH), one of the most common neurological conditions worldwide. Representing the first minimally invasive treatment for CH, the eShunt device offers the potential to result in significant benefits over current treatment, a half-century-old neurosurgical procedure associated with frequent failure, infection risk and high costs. Study data will be available in 2021. ....

United States , Buenos Aires , Distrito Federal , El Salvador , Tufts Medical Center , Dan Levangie , Clinica Sagrada Familia , Carl Heilman , Pedro Lylyk , Adel Malek , Diana Gray , University Of Buenos Aires , University Of Ciencias Empresariales , Department Of Vascular Medicine , Department Of Neurosurgery , Hydrocephalus Association , University Of El Salvador , Endovascular Surgery Division At Tufts Medical Center , Prnewswire Cerevasc Inc , Cerevasc Co , Cerevasc Inc , Shunt System , Endovascular Surgery Division , Endovascular Treatment , Communicating Hydrocephalus , Principal Investigator ,